Prostate Cancer — Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Citation(s)
A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67